Targeted Oncology Staff

Phase 3 data show giredestrant plus palbociclib misses significant PFS gain vs letrozole, with similar safety, guiding future trials.

FDA greenlights eight May 2026 oncology approvals, debuting first PROTAC, expanding breast ADCs, and advancing biomarker-driven bladder cancer and rare blood cancers.

During a live event, Amit Mahipal, MD, and participants discussed how to recognize and manage immune-related adverse events arising from combination regimens for unresectable HCC.

These 5 noteworthy abstracts provide a deeper dive into the 2026 ASCO gastrointestinal cancers data.

5 noteworthy abstracts from a deeper dive into the ASCO genitourinary cancers data.

During a live event, Christopher Lieu, MD, and participants discussed selecting third-line therapy for KRAS wild-type metastatic colorectal cancer.

“Further investigation of intravesical rBCG in combination with next-generation systemic regimens in randomized trials is warranted,” said Richard Cathomas, MD.

Oncologists weigh second-line options after ICI failure in metastatic ccRCC, spotlighting lenvatinib/everolimus, new agents, and ICI rechallenge.

During a live event, Firas El Chaer, MD, highlighted pivotal data informing decision making in frontline polycythemia vera.

During a live event, Amit Mahipal, MD, and participants discussed first-line treatment selection for unresectable or metastatic hepatocellular carcinoma.

“The use of GLP-1 drugs [vs] DPP-4 inhibitors…was associated with a meaningful reduction in cancer progression,” Mark David Orland, MD.

The study is the first randomized, prospective head-to-head comparison of the cognitive effects of two androgen receptor pathway inhibitors.

The ASCO 2026 lung cancer data include results for amivantamab, lazertinib, pumitamig, silevertinib, and sacituzumab tirumotecan.

During a live event, Thomas Hutson, DO, PharmD, PhD, and participants discussed current best practice with adjuvant IO post-nephrectomy.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed how they use PD-1 inhibitors in patients with upper gastrointestinal cancers.

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Dr Stein reviews PEACE-3 data supporting radium-223 plus enzalutamide in mCRPC and the role of bone-protecting agents in this setting.

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.

Shagufta Shaheen, MD, discusses treatment strategies for pancreatic NETs.

Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for biomarkers in ES-SCLC.

From pancreatic cancer breakthroughs to pivotal FDA votes, this week’s oncology news highlights progress, setbacks, and shifting regulatory momentum.

Explore the April 2026 FDA oncology roundup: full approval for brexu-cel in MCL, priority reviews for I-DXd and zanidatamab, and key lung cancer NDA news.

Expert insights from Shagufta Shaheen, MD, on sequencing PRRT, everolimus, and cabozantinib after SSA progression in advanced GI NETs, balancing PFS gains and tolerability.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed key considerations for biomarker testing in upper GI cancers.

Mark Stein, MD, explores managing mHSPC through PSMA PET imaging, tumor burden assessment, and AMPLITUDE trial data while considering clinical context.

Clinicians discuss using KEAP1/STK11 mutations to guide CTLA-4 therapy escalation in NSCLC, aiming to overcome PD-1 resistance and improve 5-year survival goals.

During a Case-Based Roundtable event, Thomas LeBlanc, MD, discussed risk stratification and the latest data regarding luspatercept and imetelstat for lower-risk MDS.

During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.

Explore real-world extensive-stage SCLC care, with frontline chemoimmunotherapy, steep therapy attrition, NCCN updates, and evidence favoring 4 chemotherapy cycles.

During a live event, participants discuss barriers to access and bridging strategies for tumor-infiltrating lymphocytes in melanoma.